Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There are various regimens for thromboprophylaxis after hip replacement. Low-molecular-weight heparins such as enoxaparin predominantly inhibit factor Xa but also inhibit thrombin to some degree. Orally active, specific factor Xa inhibitors such as apixaban may provide effective thromboprophylaxis with a lower risk of bleeding and improved ease of use. METHODS: In this double-blind, double-dummy study, we randomly assigned 5407 patients undergoing total hip replacement to receive apixaban at a dose of 2.5 mg orally twice daily or enoxaparin at a dose of 40 mg subcutaneously every 24 hours. Apixaban therapy was initiated 12 to 24 hours after closure of the surgical wound; enoxaparin therapy was initiated 12 hours before surgery. Prophylaxis was continued for 35 days after surgery, followed by bilateral venographic studies. The primary efficacy outcome was the composite of asymptomatic or symptomatic deep-vein thrombosis, nonfatal pulmonary embolism, or death from any cause during the treatment period. Patients were followed for an additional 60 days after the last intended dose of study medication. RESULTS: A total of 1949 patients in the apixaban group (72.0%) and 1917 patients in the enoxaparin group (71.0%) could be evaluated for the primary efficacy analysis. The primary efficacy outcome occurred in 27 patients in the apixaban group (1.4%) and in 74 patients in the enoxaparin group (3.9%) (relative risk with apixaban, 0.36; 95% confidence interval [CI], 0.22 to 0.54; P<0.001 for both noninferiority and superiority; absolute risk reduction, 2.5 percentage points; 95% CI, 1.5 to 3.5). The composite outcome of major and clinically relevant nonmajor bleeding occurred in 129 of 2673 patients assigned to apixaban (4.8%) and 134 of 2659 assigned to enoxaparin (5.0%) (absolute difference in risk, -0.2 percentage points; 95% CI, -1.4 to 1.0). CONCLUSIONS: Among patients undergoing hip replacement, thromboprophylaxis with apixaban, as compared with enoxaparin, was associated with lower rates of venous thromboembolism, without increased bleeding. (Funded by Bristol-Myers Squibb and Pfizer; ClinicalTrials.gov number, NCT00423319.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The WARFASA 309 and ASPIRE 318 trials compared aspirin, 100 mg daily, with placebo for secondary prevention of recurrent VTE for patients with an initial unprovoked event, and the pooled results of the 2 trials showed a decrease in recurrent VTE, as well as major vascular events, without an increased risk for clinically relevant bleeding. 309,315”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [318]
In the citing paper
“The investigation into the use of the lower doses of these 2 anticoagulants for secondary prevention was prompted by the desire to reduce the risk of bleeding, as well as the documented efficacy of the lower doses to prevent VTE after elective hip or knee arthroplasty. 317-321”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [318]
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Self-citationSCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Prevention of Venous Thromboembolism
Geerts, W. H., Heit, J. A., Clagett, G. P., Pineo, G. F., Colwell, C. W., Anderson, F. A., & Wheeler, H. B. (2001) · Chest · doi:10.1378/chest.119.1_suppl.132s · Cited by 4,373
Self-citationPrevention of Venous Thromboembolism
Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., & Colwell, C. W. (2008) · Chest · doi:10.1378/chest.08-0656 · Cited by 3,829
Self-citationSCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Self-citationDabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,109
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Self-citationRivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800374 · Cited by 1,433
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
Lassen, M. R., Ageno, W., Borris, L. C., Lieberman, J. R., Rosencher, N., Bandel, T. J., Misselwitz, F., & Turpie, A. G. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa076016 · Cited by 1,295
Self-citation
Cited by
Items 101–200 of 780
Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban
Frost, C. E., Shenker, A., Gandhi, M. D., Pursley, J. M., Barrett, Y. C., Wang, J. J. J., Zhang, D., Byon, W., Boyd, R. A., & LaCreta, F. P. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12393 · Cited by 63
Loke, Y. K., Pradhan, S., Yeong, J. K.-Y., & Kwok, C. S. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12376 · Cited by 63
Current Clinical Trials on the Use of Direct Oral Anticoagulants in the Pediatric Population
von Vajna, E., Alam, R., & So, T.-Y. (2016) · Cardiology and Therapy · doi:10.1007/s40119-015-0054-y · Cited by 61
“complications in adult patients who have undergone hip or knee replacement [35, 36].”
BackgroundNew oral anticoagulants: appropriateness of prescribing in real‐world setting
Pattullo, C., Barras, M. A., Tai, B., McKean, M., & Donovan, P. J. (2016) · Internal Medicine Journal · doi:10.1111/imj.13118 · Cited by 61
Lieberman, J. R., Cheng, V. C., & Cote, M. P. (2016) · The Journal of Arthroplasty · doi:10.1016/j.arth.2016.09.006 · Cited by 59
Leil, T. A., Frost, C., Wang, X., Pfister, M., & LaCreta, F. P. (2014) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2014.34 · Cited by 57
Diretrizes Brasileiras de Antiagregantes Plaquetários e Anticoagulantes em Cardiologia
Filho, A. M. L., Azmus, A., Soeiro, A., Quadros, A., Avezum, Á., Marques, A., Franci, A., Manica, A., Volschan, A., de Paola, A., et al. (2013) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.2013s009 · Cited by 95
Burr, N. E., Lummis, K., Sood, R., Kane, J. S., & Subramanian, V. (2016) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30162-5 · Cited by 60
Direct oral anticoagulant considerations in solid organ transplantation: A review
Salerno, D. M., Tsapepas, D. S., Papachristos, A., Chang, J., Martin, S. T., Hardy, M. A., & McKeen, J. T. (2016) · Clinical Transplantation · doi:10.1111/ctr.12873 · Cited by 55
Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review
Bikdeli, B., Tajrishi, F. Z., Sadeghipour, P., Talasaz, A. H., Fanikos, J. R., Lippi, G., Siegal, D. M., Eikelboom, J. W., Monréal, M., Jiménez, D., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.1292 · Cited by 61
Wang, J. J., Song, Y. J., Pursley, J. M., Wastall, P., Wright, R. N., LaCreta, F. P., Frost, C. E., & Barrett, Y. C. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-09-0634 · Cited by 56
“Cmax (ng/ml) 96 (28) 106 (25) 110 (19) 1.”
BackgroundInfluentialRivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
Cohen, A. T., Spiro, T. E., & Spyropoulos, A. C. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1303641 · Cited by 54
Risk of Pulmonary Embolism More Than 6 Weeks After Surgery Among Cancer-Free Middle-aged Patients
Caron, A., Depas, N., Chazard, E., Yelnik, C., Jeanpierre, E., Paris, C., Beuscart, J., & Ficheur, G. (2019) · JAMA Surgery · doi:10.1001/jamasurg.2019.3742 · Cited by 54
Tabatabaee, R. M., Rasouli, M. R., Maltenfort, M., & Parvizi, J. (2014) · The Journal of Arthroplasty · doi:10.1016/j.arth.2014.08.018 · Cited by 52
“Some studies have shown better efficacy for new agents such as oral direct factor Xa inhibitor over other modalities in prevention of DVT [38–41].”
BackgroundUse of New Oral Anticoagulants in Antiphospholipid Syndrome
Arachchillage, D. J., & Cohen, H. (2013) · Current Rheumatology Reports · doi:10.1007/s11926-013-0331-5 · Cited by 55
Agaba, P., Kildow, B. J., Dhotar, H. S., Seyler, T. M., & Bolognesi, M. P. (2017) · Journal of Orthopaedics · doi:10.1016/j.jor.2017.08.002 · Cited by 54
Weinberg, E. M., Palecki, J., & Reddy, K. R. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1679934 · Cited by 56
Novel anticoagulants: general overview and practical considerations for dental practitioners
Elad, S., Marshall, J., Meyerowitz, C., & Connolly, G. (2015) · Oral Diseases · doi:10.1111/odi.12371 · Cited by 51
Wu, T., Lv, C., Wu, L., Chen, W., Lv, M., Jiang, S., & Zhang, J. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10448-2 · Cited by 54
Management of heparin-induced thrombocytopenia
Warkentin, T. E., & Greinacher, A. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000273 · Cited by 52
Bensi, C., Belli, S., Paradiso, D., & Lomurno, G. (2018) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2018.03.016 · Cited by 50
Radadiya, D. K., Devani, K., Brahmbhatt, B. S., & Reddy, C. M. (2021) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002035 · Cited by 55
Migliorini, F., Maffulli, N., Velaj, E., Bell, A., Kämmer, D., Hildebrand, F., Hofmann, U. K., & Eschweiler, J. (2024) · Journal of Orthopaedics and Traumatology · doi:10.1186/s10195-023-00742-2 · Cited by 50
“1 PRISMA flow diagram of the search result 17, 19, 34, 37–41, 43–47, 49, 56].”
BackgroundInfluentialLiew, A., Eikelboom, J. W., O'Donnell, M. J., & Hart, R. G. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.04.013 · Cited by 58
Lindquist, D. E., Stewart, D. W., Brewster, A., Waldroup, C., Odle, B. L., Burchette, J. E., & El‐Bazouni, H. (2018) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029618772337 · Cited by 52
Douxfils, J., Tamigniau, A., Châtelain, B., Goffinet, C., Dogné, J.-M., & Mullier, F. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-24 · Cited by 53
“Compared to LMWHs, these agents also proved their non-inferiority or superiority for initial treatment of venous thromboembolism and for thromboprophylaxis in patients undergoing hip or knee arthroplasty, [10-20].”
BackgroundWarfarin Versus New Agents: Interpreting the Data
Ansell, J. (2010) · Hematology · doi:10.1182/asheducation-2010.1.221 · Cited by 52
Song, Y., Chang, M., Suzuki, A., Frost, R. J. A., Kelly, A., LaCreta, F., & Frost, C. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.05.004 · Cited by 43
Venous Thromboembolism Prophylaxis in Major Orthopedic Surgeries and Factor XIa Inhibitors
Jones, A., & Al‐Horani, R. A. (2023) · Medical Sciences · doi:10.3390/medsci11030049 · Cited by 55
The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery
Rachidi, S., Aldin, E. S., Greenberg, C. S., Sachs, B. L., Streiff, M. B., & Zeidan, A. M. (2013) · Expert Review of Hematology · doi:10.1586/17474086.2013.853430 · Cited by 47
Russell, R. D., & Huo, M. H. (2013) · The Journal of Arthroplasty · doi:10.1016/j.arth.2013.02.016 · Cited by 48
Enoxaparin: a pharmacologic and clinical review
Iqbal, Z., & Cohen, M. C. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.570261 · Cited by 47
Ageno, W., & Beyer‐Westendorf, J. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-06-0484 · Cited by 46
Morales, R., Ruff, E. S., Patronella, C. K., Mentz, H. A., Newall, G., Hustak, K. L., Fortes, P., & Bush, A. E. (2016) · Aesthetic Surgery Journal · doi:10.1093/asj/sjv243 · Cited by 45
A Practical Review of the Emerging Direct Anticoagulants, Laboratory Monitoring, and Reversal Agents
Joppa, S., Salciccioli, J. D., Adamski, J., Patel, S. I., Wysokiński, W. E., McBane, R. D., Al‐Saffar, F., Esser, H., & Shamoun, F. E. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7020029 · Cited by 49
Peri-Procedural Management of Oral Anticoagulants in the DOAC Era
Barnes, G. D., & Mouland, E. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.03.002 · Cited by 44
Use of direct oral anticoagulants in daily practice.
Almarshad, F., Alaklabi, A. A., Bakhsh, E., Pathan, A. R., & Almegren, M. (2018) · Europe PMC (PubMed Central) · Cited by 50
Viarasilpa, T., Panyavachiraporn, N., Marashi, S. M., Harn, M. V., Kowalski, R. G., & Mayer, S. A. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004306 · Cited by 48
Suen, K., Westh, R., Churilov, L. P., & Hardidge, A. J. (2017) · The Journal of Arthroplasty · doi:10.1016/j.arth.2017.04.010 · Cited by 44
Novel Oral Anticoagulants and Their Role in Clinical Practice
Wittkowsky, A. K. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.12.1175 · Cited by 46
Kim, S., Moon, Y., Lim, S., Kim, D.-W., & Park, Y.-S. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-07-0527 · Cited by 44
Popular naturally occurring antioxidants as potential anticoagulant drugs
Bijak, M., Saluk, J., Szelenberger, R., & Nowak, P. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2016.07.022 · Cited by 45
Meta-analysis on risk of bleeding with apixaban in patients with renal impairment
Pathak, R., Pandit, A., Karmacharya, P., Aryal, M. R., Ghimire, S., Poudel, D. R., & Shamoun, F. E. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.10.042 · Cited by 41
Chan, N., Siegal, D. M., Lauw, M. N., Ginsberg, J. S., Eikelboom, J. W., Guyatt, G. H., & Hirsh, J. (2014) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-014-1153-7 · Cited by 43
Direct Oral Anticoagulants—Pharmacology, Drug Interactions, and Side Effects
Dempfle, C.-E. H. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.03.005 · Cited by 43
Mar, P. L., Familtsev, D., Ezekowitz, M. D., Lakkireddy, D., & Gopinathannair, R. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.09.035 · Cited by 43
“All of the NOACs available on the market have been shown to be as efficacious as LMWH in the prevention of VTE following total hip and total knee arthroplasty, and resuming respective NOACs post-operatively will offer effective VTE prevention [49–56].”
BackgroundWade, R., Sideris, E., Paton, F., Rice, S. J. C., Palmer, S., Fox, D., Woolacott, N. F., & Spackman, E. (2015) · Health Technology Assessment · doi:10.3310/hta19980 · Cited by 43
Guo, W., Chen, X., Tian, X., & Li, L. (2019) · Clinical Epidemiology · doi:10.2147/clep.s219335 · Cited by 41
Alimohammadi, E., Khedri, M., Jahromi, A. M., Maleki, R., & Rezaian, M. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s265140 · Cited by 43
Maleki, R., Jahromi, A. M., Mohaghegh, S., Rezvantalab, S., Khedri, M., & Tayebi, L. (2021) · Applied Surface Science · doi:10.1016/j.apsusc.2021.150629 · Cited by 40
Song, Y. J., Wang, X., Perlstein, I., Wang, J. J., Badawy, S. I. F., Frost, C. E., & LaCreta, F. P. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.05.497 · Cited by 41
Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
Upreti, V., Song, Wang, Byon, Boyd, Pursley, LaCreta, & Frost (2013) · Clinical Pharmacology: Advances and Applications · doi:10.2147/cpaa.s41999 · Cited by 40
He, T., Han, F., Wang, J., Hu, Y., & Zhu, J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250096 · Cited by 40
Venous Thromboembolism (VTE) Prophylaxis for Hip and Knee Arthroplasty: Changing Trends
Budhiparama, N. C., Abdel, M. P., Ifran, N. N., & Parratte, S. (2014) · Current Reviews in Musculoskeletal Medicine · doi:10.1007/s12178-014-9207-1 · Cited by 42
Potential antidotes for reversal of old and new oral anticoagulants
Suryanarayan, D., & Schulman, S. (2014) · Thrombosis Research · doi:10.1016/s0049-3848(14)50026-6 · Cited by 42
“Apixaban was also compared to enoxaparin in patients undergoing knee [24,25] and hip replacement surgery [26] and was shown to be equally effective with significantly fewer bleeding complications.”
A New Generation of Oral Direct Anticoagulants
Soff, G. A. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.242834 · Cited by 46
Pariser, J. J., Soto-Avilés, O., Miller, B. C., Husainat, M. M., & Santucci, R. A. (2018) · Urology · doi:10.1016/j.urology.2018.05.029 · Cited by 39
Venous thromboembolism in orthopedic surgery: Global guidelines
Uzel, K., Azboy, İ., & Parvizi, J. (2023) · Acta Orthopaedica et Traumatologica Turcica · doi:10.5152/j.aott.2023.23074 · Cited by 42
“There is moderate-to-low-level evidence supporting the use of LMWH, aspirin, or rivaroxaban for preventing PE and symptomatic DVT.”
BackgroundInfluentialSaraf, K., Morris, P., Garg, P., Sheridan, P. J., & Storey, R. F. (2014) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2014-132605 · Cited by 42
Apixaban: A novel oral inhibitor of factor Xa
Nutescu, E. A. (2012) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110418 · Cited by 39
Cohen, A. T., Drost, P., Marchant, N., Mitchell, S., Orme, M. E., Rublee, D. A., Simon, T. A., & Sutton, A. J. (2012) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029612437579 · Cited by 46
“Clinical trials in patients who have undergone elective THR and TKR have demonstrated that apixaban has improved efficacy, when compared with enoxaparin, in reducing VTE and all-cause death, with a similar or lower risk of bleeding.(13,14) The aim of this systematic review and meta-analysis was to compare the efficacy…”
BackgroundWhat Surgeons Should Know About Non–Vitamin K Oral Anticoagulants: A Review
Verma, A., Ha, A. C. T., Rutka, J. T., & Verma, S. (2018) · JAMA Surgery · doi:10.1001/jamasurg.2018.0374 · Cited by 42
Pineo, G. F., Gallus, A. S., Raskob, G. E., CHEN, D., Ramirez, L. M., Ramacciotti, E., Lassen, M. R., & Wang, L. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12109 · Cited by 42
Self-citationRoberts, C., Horner, D. E., Coleman, G., Maitland, L., Curl-Roper, T., Smith, R., Wood, E., & Mackway-Jones, K. C. (2013) · Emergency Medicine Journal · doi:10.1136/emermed-2013-203134 · Cited by 38
“The increasing emergence of studies supporting the prophylactic use of oral factor Xa inhibitors in orthopaedic surgery (48, 49) will no doubt lead to wider use of these drugs within thromboembolism research.”
BackgroundApixaban: an Oral Direct Factor-Xa Inhibitor
Jiménez, D., Yusen, R. D., & Ramacciotti, E. (2012) · Advances in Therapy · doi:10.1007/s12325-012-0003-2 · Cited by 42
“5 mg twice daily), started 12–24 hours after wound closure, compared with subcutaneous enoxaparin 40 mg once daily, started 12 hours before surgery, for the prevention of VTE after THR surgery [28].”
BackgroundMethodYoshida, R. D. A., Yoshida, W. B., Maffei, F. H. D. A., Dib, R. E., Nunes, R., & Rollo, H. A. (2013) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2012.06.010 · Cited by 41
Direct oral anticoagulants and venous thromboembolism
Franchini, M., & Mannucci, P. M. (2016) · European Respiratory Review · doi:10.1183/16000617.0025-2016 · Cited by 40
Anticoagulantes orales directos: puesta al día
Franco‐Moreno, A., Díaz, R. M. M., & Navarro, M. J. G. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.11.042 · Cited by 39
Hamidi, M., Zeeshan, M., Kulvatunyou, N., Mitra, H. S., Hanna, K., Tang, A. L., Northcutt, A., O’Keeffe, T., & Joseph, B. A. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14439 · Cited by 37
Frost, C. E., Cui, Y., Song, Y. J., Wang, J. J. J., Yu, Z., Schuster, A. E., & Barrett, Y. C. (2013) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s51981 · Cited by 38
Fernandez‐Martinez, S., Lenoir, C., Samer, C. F., & Rollason, V. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.647 · Cited by 39
Recommendations from the ICM-VTE: General
Delegates, T. I.-V. G. (2022) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.21.01531 · Cited by 38
Caldeira, D., Canastro, M., Barra, M., Ferreira, A., Costa, J. N., Pinto, F. J., & Ferreira, J. J. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.0985 · Cited by 39
Mandernach, M. W., Beyth, R. J., & Rajasekhar, A. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s68010 · Cited by 40
“Data from the ADVANCE-3 trial led to the FDA approval of apixaban for prevention of DVT following hip replacement surgery.(23) In this study, 5,407 patients undergoing THR or revision of a previously inserted hip prosthesis were randomly assigned to receive apixaban 2.”
MethodLü, X., & Jin, L. (2018) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-018-2215-3 · Cited by 44
New and Emerging Anticoagulant Therapy for Atrial Fibrillation and Acute Coronary Syndrome
Davis, E. M., Packard, K. A., Knezevich, J. T., & Campbell, J. A. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.10.975 · Cited by 35
Cohen, A. T., Imfeld, S., Markham, J., & Granziera, S. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.11.036 · Cited by 38
“These studies have demonstrated reductions in VTE risk of up to 70% compared with standard of care, without significant increases in the risk of major bleeding [33–40,45,46].”
BackgroundMethodResultInfluentialThe Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations
Caterina, R. D., Ageno, W., Agnelli, G., Chan, N., Diener, H., Hylek, E. M., Raskob, G. E., Siegal, D. M., Verheugt, F. W. A., Lip, G. Y. H., et al. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1675816 · Cited by 37
Self-citationLeijtens, B., de Hei, K. K.-V., Jansen, J., & Koëter, S. (2014) · Archives of Orthopaedic and Trauma Surgery · doi:10.1007/s00402-014-2034-4 · Cited by 35
Klaassen, Z. W. A., Arora, K., Goldberg, H., Chandrasekar, T., Wallis, C. J. D., Sayyid, R. K., Fleshner, N. E., Finelli, A., Kutikov, A., Violette, P. D., et al. (2017) · The Journal of Urology · doi:10.1016/j.juro.2017.08.130 · Cited by 37
Fujita, Y., Nakatsuka, H., Namba, Y., Mitani, S., Yoshitake, N., Sugimoto, E., & Hazama, K. (2014) · Journal of Anesthesia · doi:10.1007/s00540-014-1891-x · Cited by 34
Wangge, G., Roes, K. C. B., de Boer, A., Hoes, A. W., & Knol, M. J. (2012) · Canadian Medical Association Journal · doi:10.1503/cmaj.120142 · Cited by 35
Matharu, G. S., Garriga, C., Whitehouse, M. R., Rangan, A., & Judge, A. (2020) · The Journal of Arthroplasty · doi:10.1016/j.arth.2020.04.088 · Cited by 36
Nederpelt, C. J., Bijman, Q., Krijnen, P., & Schipper, I. B. (2021) · Injury · doi:10.1016/j.injury.2021.11.052 · Cited by 38
Fatal pulmonary embolism following elective total hip arthroplasty: a 12-year study
Bayley, E. J., Brown, S., Bhamber, N., & Howard, P. W. (2016) · The Bone & Joint Journal · doi:10.1302/0301-620x.98b5.34996 · Cited by 39
Oh, H. J., Ryu, K. H., Park, B. J., & Yoon, B. (2021) · Medicine · doi:10.1097/md.0000000000025216 · Cited by 34
Lee, F. M. H., Chan, A. K. C., Lau, K. K., & Chan, H. H. W. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.01.031 · Cited by 33
Venous Thromboembolism in Neurocritical Care Patients
Viarasilpa, T., Panyavachiraporn, N., Jordan, J., Marashi, S. M., Harn, M. V., Akioyamen, N. O., Kowalski, R. G., & Mayer, S. A. (2019) · Journal of Intensive Care Medicine · doi:10.1177/0885066619841547 · Cited by 34
“001 Hospital length of stay, days 22 [15-36] 8 [5-15] <.”
Pandor, A., Horner, D. E., Davis, S., Goodacre, S. W., Stevens, J., Clowes, M., Hunt, B. J., Nokes, T., Keenan, J., & de Wit, K. (2019) · Health Technology Assessment · doi:10.3310/hta23630 · Cited by 38
Mahmoudi, M., & Sobieraj, D. M. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1269 · Cited by 34
Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism
Giustozzi, M., Franco, L., Vedovati, M. C., Becattini, C., & Agnelli, G. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01878-x · Cited by 38
Hernandez, C. M. R., & Garcia, D. A. (2013) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0032-1333536 · Cited by 34
Odds ratio vs risk ratio in randomized controlled trials
Balasubramanian, H., Ananthan, A., Rao, S. C., & Patole, S. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1022494 · Cited by 34
“8 [39] 16 Stone 2010 101 2416 81 1195 0.”
Chan, N., Stehouwer, A. C., Hirsh, J., Ginsberg, J. S., Alazzoni, A., Coppens, M., Guyatt, G. H., & Eikelboom, J. W. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-12-1006 · Cited by 37
Historical perspective and future direction of coagulation research
Saito, H., Matsushita, T., & Kojima, T. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04362.x · Cited by 35
Lewis, S., Glen, J., Dawoud, D., Dias, S., Cobb, J. K., Griffin, X. L., Reed, M., Sharpin, C., Stansby, G. P., & Barry, P. (2019) · Value in Health · doi:10.1016/j.jval.2019.02.013 · Cited by 31
Practical issues, limitations, and periprocedural management of the NOAC’s
Connolly, G. C., & Spyropoulos, A. C. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-0911-2 · Cited by 31
Moving Toward a More Ideal Anticoagulant
King, C. S., Holley, A. B., & Moores, L. K. (2013) · CHEST Journal · doi:10.1378/chest.12-1362 · Cited by 32
Direct oral anticoagulants: An update
Franco‐Moreno, A., Díaz, R. M. M., & Navarro, M. J. G. (2018) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2018.07.005 · Cited by 34
Prophylaxis and treatment of venous thromboembolism in the critically ill
Adriance, S. M., & Murphy, C. V. (2013) · International Journal of Critical Illness and Injury Science · doi:10.4103/2229-5151.114274 · Cited by 35
“…factor Xa inhibitor Prevention of stroke and systemic embolism in nonvalvular atrial fibrillation [57] Postoperative thromboprophylaxis in hip or knee replacement surgery [58] Prophylaxis:N/aTherapeutic Anticoagulation: Acute DVT [59] VTE: Venous thromboembolism, FDA: Food & Drug Administration”
Metadata
- Authors
- Lassen, M. R., Gallus, A., Raskob, G. E., Pineo, G., Chen, D., & Ramirez, L. M.
- Affiliations
- University of Copenhagen (DK)
- South Australia Pathology (AU)
- University of Oklahoma Health Sciences Center (US)
- University of Calgary (CA)
- Bristol-Myers Squibb (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-12-23
- Volume
- 363
- Issue
- 26
- Pages
- 2487-2498
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2133686162
- Cited by
- 775
- References
- 35
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 32 · 2023: 18 · 2022: 25 · 2021: 33 · 2020: 34 · 2019: 39 · 2018: 41 · 2017: 39 · 2016: 62 · 2015: 66 · 2014: 67 · 2013: 121 · 2012: 102
- FWCI
- 76.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Murdoch University Research Portal (submittedVersion)
- Flinders Academic Commons (Flinders University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, enoxaparin, thromboprophylaxis, total hip arthroplasty, factor Xa inhibitors, low molecular weight heparin, deep vein thrombosis, pulmonary embolism, bleeding risk, venography, non-inferiority, postoperative thromboprophylaxis, oral anticoagulants, venous thromboembolism
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Anticoagulants, Double-Blind Method, Female, Hemorrhage, Humans, Injections, Subcutaneous, Male, Middle Aged, Postoperative Complications, Pyrazoles, Pyridones, Confidence Intervals, Treatment Outcome, Enoxaparin, Arthroplasty, Replacement, Hip, Venous Thromboembolism, Young Adult, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.